For Immediate ReleaseOctober 30, 2020

Sumitomo Chemical Reports
Consolidated Financial Results
For the Half-Year Ended September 30, 2020
For the half-year ended on September 30, 2020, the Sumitomo Chemical Group
reported consolidated sales revenue of ¥1,046.8 billion, decrease of ¥60.8 billion year
on year, core operating income* of ¥54.1 billion, operating income of ¥50.8 billion, andloss attributable to owners of the parent of ¥1.1 billion; all lower than the results fromthe same period of the previous year.
Sumitomo Chemical decided to pay an interim dividend of ¥6 per share.
*: Core operating income is a gain and loss concept, reflecting recurring earning
capacity, and deducts gains and losses incurred by non-recurring factors fromoperating income. It includes the share of profit of investments accounted for using
the equity method.
The financial results by business segment for the half-year are as follows:
Petrochemicals & Plastics
Amid the economic downturn due to the COVID-19 pandemic, shipment of synthetic
resins mainly for automotive use declined. Impacted by a drop in market prices for
raw materials, the prices of petrochemical products hovered around at a low level. Asa result, sales revenue declined by ¥108.6 billion from the same period of the previousyear to ¥243.6 billion. Core operating income suffered a loss of ¥31.3 billion, declinedby ¥48.7 billion from the same period of the previous year, affected by decreased
shipment volume, deteriorated margins of petrochemical products, and periodic
shutdown maintenance at Rabigh Refining and Petrochemical Company, our equity
method investee.

Energy & Functional Materials
Impacted by COVID-19 pandemic, shipments of materials for automotive use
decreased, including synthetic rubber, and separators and cathode materials forlithium-ion secondary batteries. As a result, sales revenue dropped by ¥25.8 billion
from the same period of the previous year to ¥105.2 billion, and core operating income
declined by ¥7.8 billion from the same period of the previous year to ¥4.8 billion.
IT-related Chemicals
Shipments of processing materials for semiconductors (including high purity
chemicals and photoresists) increased driven by growing demand for these items.
Meanwhile, shipment of materials for display applications increased in the face ofstay-at-home demand and telework demand. As a result, sales revenue increased by¥6.4 billion from the same period of the previous year to ¥213.3 billion, and core
operating income increased by ¥6.8 billion from the same period of the previous yearto ¥22.1 billion
Health & Crop Sciences
Sales of crop protection products increased after the acquisition of four SouthAmerican subsidiaries of Nufarm in April 2020. Market prices of methionine (feedadditive) increased from the same period of the previous year. As a result, sales
revenue increased by ¥39.7 billion from the same period of the previous year to ¥186.1billion. Core operating income recovered from a year earlier loss to ¥9.9 billion,increase of ¥18.1 billion from the same period of the previous year due to the improved
margins of methionine and other factors.
Pharmaceuticals
Sales increased in Japan, driven by Equa® and EquMet® (for type II diabetes
mellitus) launched in the previous fiscal year. In North America, sales of Latuda®
(atypical antipsychotic agent) increased. As a result, sales revenue increased by¥28.7 billion from the same period of the previous year to ¥276.1 billion. Core
operating income increased by ¥2.2 billion from the same period of the previous yearto ¥49.1 billion due to increased sales revenue despite that sales expenses, generaland administrative expenses (SG&A) and research and development expenses
increased after the expenses at Sumitovant Biopharma and its subsidiaries (whichwere acquired as part of the strategic alliance with Roivant Sciences Ltd., in theprevious fiscal year) were recognized.

Others
In addition to the above five segments, the Sumitomo Chemical Group supplies
electric power and steam, designs chemical plants/supervises the construction of
those facilities, provides transportation and warehousing, and conducts physicalproperty analysis/environmental analysis. Sales revenue of these businesses
declined by ¥1.3 billion from the same period of the previous year to ¥22.5 billion, andcore operating income increased by ¥0.5 billion from the same period of the previous
year to ¥5.7 billion.

Summary of Consolidated Results(1) Results of Operations:
Sales revenue
Core operating income(Share of profit of investments
accounted for using the equity method )Operating income
Income before taxes
Net income
Net income attributable tonon-controlling interests
Net income (loss) attributable toowners of the parent

Net income (loss) per 1,000 shares

Comprehensive income(6 Months ended
September 30, 2020
Yen (Millions)
USD (Thousands)*
1,046,771
9,893,866
54,066
511,021(22,973) )((217,136) )6 Months ended
September 30, 2019
Yen (Millions)
1,107,558
84,527(12,211 )

50,776
38,84015,425479,924
367,108
145,794

102,545
96,64150,081

16,514

156,087

20,372(1,089)(10,293)

29,709Yen(666)

USD*
(6)

Yen
18,171

Yen (Millions)(9,285)

USD (Thousands)*(87,760)

Yen (Millions)(3,855)

As of September 30, 2020
Yen (Millions)
USD (Thousands)*
3,774,355
35,674,433
1,371,240
12,960,681

As of March 31, 2020
Yen (Millions)
3,650,332
1,388,837

6 Months ended
September 30, 2020
Yen (Millions)
USD (Thousands)*
156,585
1,480,009(62,963)(595,113)
97,937925,681
381,8023,608,715

6 Months ended
September 30, 2019
Yen (Millions)
69,930(72,791)
80,297271,320

6 Months ended
September 30, 2020
Yen (Millions)
USD (Thousands)*

6 Months ended
September 30, 2019
Yen (Millions)䚷(2) Financial Position:
Total assets
Total equity(3) Cash Flows:
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period(4) Results of Operations by
䚷䚷䚷Business Segment:
Sales revenue
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersCore operating income
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments

243,630
105,229
213,259
186,050
276,141
22,462
1,046,771

2,302,741
994,6032,015,681
1,758,507
2,610,028
212,306
9,893,866

352,192
131,032
206,860
146,311247,446
23,717
1,107,558(31,283)
4,769
22,1399,914
49,054
5,668(6,195)54,066(295,681)
45,076
209,253
93,705
463,648
53,573(58,554)
511,021

17,402
12,54815,296(8,185)46,874
5,209(4,617)84,527(Note)
䚷 *:U.S. dollar amounts are translated from yen, for convenience only, at the rate ofࠉ¥105.80 = $1 prevailing on September 30, 2020.
䚷